Depressed in vitro T cell responses concomitant with augmented Interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with Interleukin-2

Jacquelyn A. Hank*, Jeffrey A. Sosman, Peter C. Kohler, Robin Bechhofer, Barry Storer, Paul M. Sondel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Peripheral blood lymphocytes obtained from cancer patients receiving interleukin-2 (IL-2) on two separate clinical protocols were evaluated for their in vitro responses to IL-2, alloantigens, and PHA. IL-2 in vivo induced enhanced in vitro proliferative responses to IL-2 and diminished in vitro proliferative responses to phytohemagglutinin (PHA) and alloantigens. Alloinduced cytotoxic T cell responses were also depressed following in vivo IL-2. We examined the kinetics of the in vitro proliferative response to PHA and IL-2 and found that while the response of lymphocytes primed in vivo with IL-2 to PHA was depressed at all times during the 2 week in vitro exposure, the response to IL-2 peaked earlier and higher than did the response to IL-2 by lymphocytes obtained prior to IL-2 therapy. These contrasting effects on an-tigen-induced T cell responses vs. IL-2 induced nonspecific proliferative and cytotoxic responses suggest the importance of dose and timing of IL-2 administration when used to enhance antigen-specific T cell responses or as an immune enhancing agent combined with vaccines.

Original languageEnglish (US)
Pages (from-to)5-14
Number of pages10
JournalJournal of Biological Response Modifiers
Volume9
Issue number1
StatePublished - Feb 1990

Keywords

  • Alloantigens
  • Interleukin-2
  • Peripheral blood lymphocytes
  • Phytohemagglutinin

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Depressed in vitro T cell responses concomitant with augmented Interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with Interleukin-2'. Together they form a unique fingerprint.

Cite this